Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss predictors of belimumab renal response in lupus nephritis, and the efficacy and safety of telitacicept in SLE with haematological involvement.

June 2024 Monthly Publications Podcast

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Doctor Antony Psarras, an NIHR Academic Clinical Lecturer in Rheumatology at the University of Oxford and at the Kennedy Institute of Rheumatology. 

Together, they discuss the use of CD163 as a marker for diagnosis and flare in lupus nephritis. They also discuss the impact of discontinuing immunosuppression on the disease, in particular looking at novel research surrounding the predictors of flares, time to withdrawal and long-term outcomes. 

If you are interested in any of the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus:  Flare Prediction and CD163 in Lupus Nephritis

Steering Committee members Professor Chris Edwards from the University Hospital Southampton NHS Foundation Trust is joined by Professor Victoria Werth, from the Philadelphia Veterans Administration Hospital, Pennsylvania, USA on the latest Lupus Forum podcast. 

Together, they discuss the efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with SLE, as well as CD19-CAR T-cell therapy inducing B cell deep tissue depletion! If you are interested in any of the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus: Sequential belimumab and rituximab treatment and CAR T-cell therapy

Steering Committee members Professor Ed Vital, who is a Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust, UK, is joined by Professor Richard Furie, who is Chief of the Division of Rheumatology at the Department of Medicine, Northwell Health, New York, and Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell, and Professor Liz Lightstone, from the Imperial College Healthcare NHS Trust Renal and Transplant Centre, Hammersmith, London, on the latest Lupus Forum podcast. 

Together, they discuss defining ANA-associated arthritis and proposing new basket trial groupings, as well as evaluating the achievement of EULAR/ERA-EDTA treatment targets in lupus nephritis and the need for therapy adjustments. If you are interested in any of the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/ 


Discussing Lupus: Defining ANA-associated arthritis and achieving treatment targets

Steering Committee member Professor Victoria Werth, who is Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Pennsylvania, USA, is joined by fellow member Professor Chi-Chiu Mok, who is Chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, on the latest Lupus Forum podcast. 

Together, they discuss the efficacy and safety of iberdomide in CLE, as well as the efficacy and safety of SGLT2i vs. DPP4i for the primary prevention of cardiovascular disease and renal events in SLE and comorbid type 2 diabetes. If you are interested in any of the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/ 


Discussing Lupus: Efficacy and safety results of iberdomide in CLE, and SGLT2i vs. DPP4i in both SLE and comorbid type 2 diabetes

Professor Vibeke Stand (Stanford University) and Professor Eric Morand (Monash University) join the latest Lupus Forum podcast to discuss LLDAS and remission in SLE patients with HDAS, as well as the latest APLAR treatment consensus for LN.. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/  

Discussing Lupus: LLDAS and remission in HDAS SLE patients and the 2024 APLAR consensus for LN

Challenges in Lupus Nephritis Highlights Podcast

Advances in SLE: Highlights Podcast

Our Steering Committee experts Professor Victoria Werth and Chris Edwards join the latest Lupus Forum podcast to discuss the effect of belimumab vs placebo on mucocutaneous manifestations of SLE, and the long-term impact of anifrolumab vs placebo on LLDAS and DORIS attainment in patients with SLE. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/  

Discussing Lupus: Belimumab in mucocutaneous lupus erythematosus and anifrolumab in SLE

Join Professors Ed Vital, Brad Rovin, Liz Lightstone, and Maria Dall'Era as they review the current standard of care, the recommended guidelines, and emerging therapies in lupus nephritis. With discussions outlining strategies to improve real-world challenges in the management and overall quality of life for these patients.

Advances in Lupus Nephritis

Join Professors Liz Lightstone and Maria Dall’Era for an expert-led discussion focused on lupus nephritis, exploring its current standard of care, practical implementation in clinical settings, and evolving treatment landscape. This podcast will delve into the latest advances in the management of lupus nephritis, including emerging therapies such as obinutuzumab, and examine the future treatment pipeline.

Advances in Lupus Nephritis Podcast

Join Professors Ed Vital, Cynthia Aranow, Richard Furie, and Chris Edwards as they discuss the role of the JAK-STAT pathway, the emerging evidence of using JAK Inhibitors in clinical trials (SLEek trial), and the need for long-term data and the challenges faced. 

JAKi in the treatment of SLE

Join Professors Ed Vital and Chris Edwards as they preview what they are most looking forward to this EULAR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.

EULAR 2025 Preview Podcast

EULAR 2025 Highlights: Day 1

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).

EULAR 2025 Highlights: Day 2

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).

EULAR 2025 Highlights: Day 3

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).


EULAR 2024 Highlights: Day 4

Our Steering Committee Member Professor Maria Dall’Era is joined by Professor Vibeke Strand in the latest Lupus Forum podcast. Together they discuss the efficacy of belimumab treatment in patients with SLE. They will also discuss the impact of long-term anifrolumab treatment on patients’ perceived health status and health-related quality of life.

If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/  


Discussing Lupus: Insights into belimumab and anifrolumab in SLE

Join Professors Ed Vital and Chris Edwards as they review their highlights of the recent EULAR 2025 congress, watch them discuss their abstracts and highlight key information.

Lupus at EULAR: 2025 Review Podcast

Join Professor Ed Vital, and Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger on the Lupus Forum in their discussion on the recent webinar “CAR-T and CAR-NK therapies: Are they the future of lupus treatment?”. Watch them discuss key highlights from the webinar including the potential of CAR-T and CAR-NK therapies as transformative treatments for lupus. Highlighting the mechanisms, applications, and the challenges of this treatment. Visit www.lupusforum.com to access the full webinar content, including detailed slide materials from Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger. 

CAR-T and CAR-NK therapies: Are they the future of lupus treatment?: Highlights Podcast

Join Professors Ed Vital and Michelle Kahlenberg as they delve into the role of the cGAS pathway in systemic lupus erythematosus (SLE). This engaging discussion covers the pathway’s relevance in disease, recent clinical trial updates on cGAS inhibitors, and their potential role in the future treatment of SLE.

cGAS Podcast

Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.

If you are interested in the paper discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/ 


Discussing Lupus: 2025 ACR Guideline for the Treatment of SLE

Join Professor Brad Rovin for an expert-led discussion focused on emerging therapies and renal outcomes in LN. This podcast will provide an overview of the effect of long-term voclosporin treatment on renal histology in patients with active LN with repeat renal biopsies, and explore how BCMA-targeted CAR T-cell therapy can effectively induce disease remission in refractory LN. 

If you are interested in the papers discussed, head on over to the Lupus Forum today! 

Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus: Emerging therapies and renal outcomes in LN

Professor Eric Morand and Professor Rangi Kandane-Rathnayake discuss the therapeutic strategies and emerging treatments in SLE and LN. This podcast provides a valuable framework for guiding therapeutic decisions for rare SLE manifestations where the available recommendations might be insufficient or inapplicable. The efficacy, PK and safety of iscalimab versus placebo as add-on to SoC therapy in patients with biopsy-proven active proliferative LN is also reported.

If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus: Therapeutic strategies and emerging treatments in SLE and LN

Join Professors Ed Vital and Maria Dall'Era as they preview what they are most looking forward to this ACR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.

Lupus at ACR 2025: Preview Podcast

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, October 26th).

ACR 2025 Highlights: Day 1

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, October 27th).

ACR 2025 Highlights: Day 2

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday, October 28th).

ACR 2025 Highlights: Day 3

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesday, October 29th).

ACR 2025 Highlights: Day 4

Join Professor Chris Edwards and Doctor Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and efficacy and safety of upadacitinib as a monotherapy or combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE, and also supporting clinical care, translational/observation research.

If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Discussing Lupus: EULAR recommendations and long-term efficacy/safety of JAKis or BTKs

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

The Lupus Forum

Popular tracks